Live feed15:00:00·14mPRReleasevia QuantisnowSRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic MalignanciesByQuantisnow·Wall Street's wire, on your screen.SRXH· SRX Health Solutions Inc.CERO· CERo Therapeutics Holdings Inc.Consumer StaplesHealth Care
